Zealand Pharma still on the rise
The biotech company Zealand Pharma presented a Q1 net surplus that was higher than in the same period last year. Turnover has also increased significantly.
af KRESTEN MORTEN MUNKSGAARD
With a net surplus of DKK 66 million and a turnover of 120 million the Danish biotech company Zealand Pharma was still on the rise in the first quarter of 2012. The numbers from the same period last year were DKK 44.9 million and a big, fat zero, respectively.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
